Hexamethonium

Identification

Name
Hexamethonium
Accession Number
DB08960
Type
Small Molecule
Groups
Experimental
Description

A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.

Structure
Thumb
Synonyms
  • N,N,N,N',N',N'-hexamethylhexane-1,6-diaminium
Product Ingredients
IngredientUNIICASInChI Key
Hexamethonium Bromide8J77X3S60355-97-0FAPSXSAPXXJTOU-UHFFFAOYSA-L
International/Other Brands
Bistrium (Bristol-Myers Squibb)
Categories
UNII
3C9PSP36Z2
CAS number
60-26-4
Weight
Average: 202.38
Monoisotopic: 202.24089897
Chemical Formula
C12H30N2
InChI Key
VZJFGSRCJCXDSG-UHFFFAOYSA-N
InChI
InChI=1S/C12H30N2/c1-13(2,3)11-9-7-8-10-12-14(4,5)6/h7-12H2,1-6H3/q+2
IUPAC Name
trimethyl[6-(trimethylazaniumyl)hexyl]azanium
SMILES
C[N+](C)(C)CCCCCC[N+](C)(C)C

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with 1,10-Phenanthroline.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Hexamethonium.Experimental
AcebutololAcebutolol may increase the hypotensive activities of Hexamethonium.Approved
AclidiniumAclidinium may increase the anticholinergic activities of Hexamethonium.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Alcuronium.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Hexamethonium.Approved, Investigational
AliskirenHexamethonium may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Alphaprodine.Illicit
AlprenololAlprenolol may increase the hypotensive activities of Hexamethonium.Approved, Withdrawn
AmbenoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Ambenonium.Approved
AmbrisentanHexamethonium may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineHexamethonium may increase the hypotensive activities of Amifostine.Approved, Investigational
AmlodipineAmlodipine may increase the hypotensive activities of Hexamethonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Hexamethonium.Approved
AtenololAtenolol may increase the hypotensive activities of Hexamethonium.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Atracurium.Experimental
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Hexamethonium.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Hexamethonium.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Benactyzine.Withdrawn
BenazeprilBenazepril may increase the hypotensive activities of Hexamethonium.Approved, Investigational
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Hexamethonium.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Hexamethonium.Withdrawn
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Hexamethonium.Approved
BepridilBepridil may increase the hypotensive activities of Hexamethonium.Approved, Withdrawn
BetaxololBetaxolol may increase the hypotensive activities of Hexamethonium.Approved
BethanidineBethanidine may increase the hypotensive activities of Hexamethonium.Approved
BezitramideThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Bezitramide.Experimental, Illicit, Withdrawn
BietaserpineBietaserpine may increase the hypotensive activities of Hexamethonium.Experimental
BimatoprostBimatoprost may increase the hypotensive activities of Hexamethonium.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Hexamethonium.Approved
BisoprololBisoprolol may increase the hypotensive activities of Hexamethonium.Approved
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Hexamethonium.Experimental
BosentanBosentan may increase the hypotensive activities of Hexamethonium.Approved, Investigational
Botulinum Toxin Type AHexamethonium may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BHexamethonium may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BQ-123Hexamethonium may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Hexamethonium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Hexamethonium.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Hexamethonium.Experimental
BupranololBupranolol may increase the hypotensive activities of Hexamethonium.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Butorphanol.Approved, Illicit, Vet Approved
CadralazineCadralazine may increase the hypotensive activities of Hexamethonium.Experimental
CafedrineHexamethonium may increase the hypotensive activities of Cafedrine.Investigational
CandesartanCandesartan may increase the hypotensive activities of Hexamethonium.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Hexamethonium.Experimental
CaptoprilCaptopril may increase the hypotensive activities of Hexamethonium.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Carfentanil.Illicit, Vet Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Hexamethonium.Withdrawn
CarteololCarteolol may increase the hypotensive activities of Hexamethonium.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Hexamethonium.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Hexamethonium.Approved, Investigational
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Hexamethonium.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Chlorphenoxamine.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Hexamethonium.Approved
CicletanineHexamethonium may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Hexamethonium.Approved
CimetropiumHexamethonium may increase the anticholinergic activities of Cimetropium.Experimental
ClonidineClonidine may increase the hypotensive activities of Hexamethonium.Approved
CloranololHexamethonium may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Coumaphos.Vet Approved
CryptenamineCryptenamine may increase the hypotensive activities of Hexamethonium.Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Hexamethonium.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Hexamethonium.Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Hexamethonium.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Hexamethonium.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Hexamethonium.Approved
DecamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Decamethonium.Approved
DelaprilHexamethonium may increase the hypotensive activities of Delapril.Experimental
DemecariumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Demecarium.Approved
DeserpidineHexamethonium may increase the hypotensive activities of Deserpidine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Hexamethonium.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Hexamethonium.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dezocine.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Hexamethonium.Approved
DichlorvosThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Hexamethonium.Approved
diethylnorsperminediethylnorspermine may increase the hypotensive activities of Hexamethonium.Investigational
DihydralazineDihydralazine may increase the hypotensive activities of Hexamethonium.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Dihydromorphine.Experimental, Illicit
DiltiazemDiltiazem may increase the hypotensive activities of Hexamethonium.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Donepezil.Approved
DorzolamideDorzolamide may increase the hypotensive activities of Hexamethonium.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Hexamethonium.Approved
DPDPEThe risk or severity of adverse effects can be increased when Hexamethonium is combined with DPDPE.Investigational
DronabinolHexamethonium may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Edrophonium.Approved
EfonidipineHexamethonium may increase the hypotensive activities of Efonidipine.Approved
EluxadolineHexamethonium may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Emepronium.Experimental
EnalaprilEnalapril may increase the hypotensive activities of Hexamethonium.Approved, Vet Approved
EnalaprilatHexamethonium may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Hexamethonium.Experimental
EpanololHexamethonium may increase the hypotensive activities of Epanolol.Experimental
EpoprostenolEpoprostenol may increase the hypotensive activities of Hexamethonium.Approved
EprosartanEprosartan may increase the hypotensive activities of Hexamethonium.Approved
EtanautineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Etanautine.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Hexamethonium.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Etybenzatropine.Experimental
FelodipineFelodipine may increase the hypotensive activities of Hexamethonium.Approved, Investigational
FenoldopamFenoldopam may increase the hypotensive activities of Hexamethonium.Approved
FentanylThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Fenthion.Vet Approved
Ferulic acidFerulic acid may increase the hypotensive activities of Hexamethonium.Experimental
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Hexamethonium.Approved
FosinoprilFosinopril may increase the hypotensive activities of Hexamethonium.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Hexamethonium.Approved, Vet Approved
GalantamineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Hexamethonium.Approved
Ginkgo bilobaThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Glucagon recombinant.Approved
GlycopyrroniumHexamethonium may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
GuanabenzGuanabenz may increase the hypotensive activities of Hexamethonium.Approved
GuanadrelGuanadrel may increase the hypotensive activities of Hexamethonium.Approved
GuanazodineHexamethonium may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Hexamethonium.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Hexamethonium.Approved, Investigational
GuanoclorHexamethonium may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzHexamethonium may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanHexamethonium may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Hexamethonium.Experimental
HeroinThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Heroin.Approved, Illicit
HomatropineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Huperzine A.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Hexamethonium.Experimental
HydralazineHydralazine may increase the hypotensive activities of Hexamethonium.Approved
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Hexamethonium.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Hexamethonium.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Hexamethonium.Approved
IloprostIloprost may increase the hypotensive activities of Hexamethonium.Approved, Investigational
ImidaprilHexamethonium may increase the hypotensive activities of Imidapril.Investigational
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Hexamethonium.Approved
IndenololIndenolol may increase the hypotensive activities of Hexamethonium.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Hexamethonium.Withdrawn
IpidacrineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hexamethonium.Approved
IproclozideIproclozide may increase the hypotensive activities of Hexamethonium.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Hexamethonium.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Hexamethonium.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Hexamethonium.Approved
IsoflurophateThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Hexamethonium.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Hexamethonium.Investigational
KetanserinKetanserin may increase the hypotensive activities of Hexamethonium.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Ketobemidone.Approved
LabetalolLabetalol may increase the hypotensive activities of Hexamethonium.Approved
LacidipineHexamethonium may increase the hypotensive activities of Lacidipine.Approved
LatanoprostLatanoprost may increase the hypotensive activities of Hexamethonium.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Hexamethonium.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Levorphanol.Approved
LinsidomineHexamethonium may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Hexamethonium.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Lofentanil.Illicit
LofexidineLofexidine may increase the hypotensive activities of Hexamethonium.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Hexamethonium.Approved
MacitentanHexamethonium may increase the hypotensive activities of Macitentan.Approved
MalathionThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Malathion.Approved, Investigational
ManidipineHexamethonium may increase the hypotensive activities of Manidipine.Approved
MazaticolThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Mazaticol.Experimental
MebanazineMebanazine may increase the hypotensive activities of Hexamethonium.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Hexamethonium.Approved
MefloquineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Hexamethonium.Approved
MethoserpidineHexamethonium may increase the hypotensive activities of Methoserpidine.Experimental
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Hexamethonium.Approved
Methyl salicylateThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Hexamethonium.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Hexamethonium.Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Hexamethonium.Approved, Investigational
MetipranololMetipranolol may increase the hypotensive activities of Hexamethonium.Approved
MetixeneThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Metixene.Approved
MetoclopramideThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Hexamethonium.Approved
MetoprololMetoprolol may increase the hypotensive activities of Hexamethonium.Approved, Investigational
MetyrosineHexamethonium may increase the hypotensive activities of Metyrosine.Approved
MianserinMianserin may increase the anticholinergic activities of Hexamethonium.Approved
MibefradilMibefradil may increase the hypotensive activities of Hexamethonium.Withdrawn
MinaprineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Minaprine.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Hexamethonium.Approved
MirabegronThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Mirabegron.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Hexamethonium.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Hexamethonium.Approved
MoexiprilMoexipril may increase the hypotensive activities of Hexamethonium.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Hexamethonium.Approved
MorphineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Hexamethonium.Approved
MuzolimineHexamethonium may increase the hypotensive activities of Muzolimine.Experimental
NabiloneHexamethonium may increase the tachycardic activities of Nabilone.Approved, Investigational
NadololNadolol may increase the hypotensive activities of Hexamethonium.Approved
NaftopidilHexamethonium may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Nalbuphine.Approved
NebivololNebivolol may increase the hypotensive activities of Hexamethonium.Approved, Investigational
NeostigmineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NialamideNialamide may increase the hypotensive activities of Hexamethonium.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Hexamethonium.Approved
NicomorphineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Nicomorphine.Experimental
NicorandilHexamethonium may increase the hypotensive activities of Nicorandil.Approved
NiguldipineHexamethonium may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Hexamethonium.Approved
NimodipineNimodipine may increase the hypotensive activities of Hexamethonium.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Hexamethonium.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Hexamethonium.Approved
NitroprussideNitroprusside may increase the hypotensive activities of Hexamethonium.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Normethadone.Approved, Illicit
ObinutuzumabHexamethonium may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Hexamethonium.Withdrawn
OlmesartanOlmesartan may increase the hypotensive activities of Hexamethonium.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Hexamethonium.Investigational
OpiumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Hexamethonium.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Otilonium.Experimental
OxitropiumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Oxitropium.Investigational
OxprenololOxprenolol may increase the hypotensive activities of Hexamethonium.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Hexamethonium.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Hexamethonium.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Hexamethonium.Approved
ParaoxonThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Paraoxon.Experimental
PargylinePargyline may increase the hypotensive activities of Hexamethonium.Approved
PenbutololPenbutolol may increase the hypotensive activities of Hexamethonium.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Hexamethonium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Hexamethonium.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Hexamethonium.Approved
PethidineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypotensive activities of Hexamethonium.Approved
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Hexamethonium.Experimental
PheniprazinePheniprazine may increase the hypotensive activities of Hexamethonium.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Phenoperidine.Experimental
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Hexamethonium.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Hexamethonium.Withdrawn
PhentolaminePhentolamine may increase the hypotensive activities of Hexamethonium.Approved
PhysostigmineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Physostigmine.Approved
PinacidilPinacidil may increase the hypotensive activities of Hexamethonium.Withdrawn
PindololPindolol may increase the hypotensive activities of Hexamethonium.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Hexamethonium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Hexamethonium.Approved
PiritramideThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Piritramide.Investigational
PirlindolePirlindole may increase the hypotensive activities of Hexamethonium.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Hexamethonium.Withdrawn
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Hexamethonium.Approved
Potassium ChlorideHexamethonium may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Hexamethonium.Approved, Investigational
PrazosinPrazosin may increase the hypotensive activities of Hexamethonium.Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Hexamethonium.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Hexamethonium.Approved
PropiverineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Propiverine.Investigational
PropranololPropranolol may increase the hypotensive activities of Hexamethonium.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Pyridostigmine.Approved
QuinaprilQuinapril may increase the hypotensive activities of Hexamethonium.Approved, Investigational
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Hexamethonium.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Hexamethonium.Approved
QuinineQuinine may increase the hypotensive activities of Hexamethonium.Approved
RamiprilRamipril may increase the hypotensive activities of Hexamethonium.Approved
RamosetronHexamethonium may increase the constipating activities of Ramosetron.Approved
RasagilineRasagiline may increase the hypotensive activities of Hexamethonium.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Remifentanil.Approved
RemikirenRemikiren may increase the hypotensive activities of Hexamethonium.Approved
RescinnamineHexamethonium may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Hexamethonium.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Hexamethonium.Investigational
RiociguatHexamethonium may increase the hypotensive activities of Riociguat.Approved
RituximabHexamethonium may increase the hypotensive activities of Rituximab.Approved
RivastigmineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Rivastigmine.Approved, Investigational
SafrazineSafrazine may increase the hypotensive activities of Hexamethonium.Withdrawn
SaprisartanSaprisartan may increase the hypotensive activities of Hexamethonium.Experimental
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Hexamethonium.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Scopolamine butylbromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Hexamethonium.Approved, Investigational
SelegilineSelegiline may increase the hypotensive activities of Hexamethonium.Approved, Investigational, Vet Approved
SelexipagHexamethonium may increase the hypotensive activities of Selexipag.Approved
SildenafilSildenafil may increase the antihypertensive activities of Hexamethonium.Approved, Investigational
SitaxentanHexamethonium may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Hexamethonium.Approved
SpiraprilSpirapril may increase the hypotensive activities of Hexamethonium.Approved
SufentanilThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Hexamethonium.Approved
TacrineThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Tacrine.Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Hexamethonium.Approved, Investigational
TalinololHexamethonium may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Tapentadol.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Hexamethonium.Approved, Investigational
TemocaprilTemocapril may increase the hypotensive activities of Hexamethonium.Experimental, Investigational
TerlipressinTerlipressin may increase the hypotensive activities of Hexamethonium.Approved, Investigational
TetrahydropalmatineHexamethonium may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineHexamethonium may increase the hypotensive activities of Theodrenaline.Investigational
TiboloneHexamethonium may increase the hypotensive activities of Tibolone.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Hexamethonium.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Tilidine.Experimental
TimololTimolol may increase the hypotensive activities of Hexamethonium.Approved
TiotropiumHexamethonium may increase the anticholinergic activities of Tiotropium.Approved
TolazolineTolazoline may increase the hypotensive activities of Hexamethonium.Approved, Vet Approved
TolonidineHexamethonium may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Hexamethonium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Hexamethonium.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Topiramate.Approved
TorasemideTorasemide may increase the hypotensive activities of Hexamethonium.Approved
TramadolThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Tramadol.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Hexamethonium.Approved
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Hexamethonium.Experimental
TranylcypromineTranylcypromine may increase the hypotensive activities of Hexamethonium.Approved
TravoprostTravoprost may increase the hypotensive activities of Hexamethonium.Approved
TreprostinilTreprostinil may increase the hypotensive activities of Hexamethonium.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Hexamethonium.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Hexamethonium.Approved
TrimazosinTrimazosin may increase the hypotensive activities of Hexamethonium.Experimental
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Hexamethonium.Approved
TropatepineThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Tropatepine.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Hexamethonium.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Hexamethonium.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Hexamethonium.Approved
UdenafilUdenafil may increase the antihypertensive activities of Hexamethonium.Approved, Investigational
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Hexamethonium.Approved
UnoprostoneUnoprostone may increase the hypotensive activities of Hexamethonium.Approved
UrapidilUrapidil may increase the hypotensive activities of Hexamethonium.Investigational
ValsartanValsartan may increase the hypotensive activities of Hexamethonium.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Hexamethonium.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Hexamethonium.Approved
VincamineHexamethonium may increase the hypotensive activities of Vincamine.Experimental
VinpocetineHexamethonium may increase the hypotensive activities of Vinpocetine.Investigational
XipamideHexamethonium may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Hexamethonium.Approved
YohimbineYohimbine may decrease the antihypertensive activities of Hexamethonium.Approved, Vet Approved
ZofenoprilHexamethonium may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 2,641,610.

General References
  1. Adams DJ, Bevan S, Terrar DA: Modes of hexamethonium action on acetylcholine receptor channels in frog skeletal muscle. Br J Pharmacol. 1991 Jan;102(1):135-45. [PubMed:1710523]
External Links
KEGG Compound
C07510
PubChem Compound
3604
PubChem Substance
310264925
ChemSpider
3478
BindingDB
50038416
ChEBI
5700
ChEMBL
CHEMBL100622
Wikipedia
Hexamethonium
ATC Codes
Not Available
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)290-291U.S. Patent 2,641,610.
Predicted Properties
PropertyValueSource
Water Solubility2.24e-05 mg/mLALOGPS
logP-3.6ALOGPS
logP-6.6ChemAxon
logS-7.1ALOGPS
Physiological Charge2ChemAxon
Hydrogen Acceptor Count0ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area0 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity88.55 m3·mol-1ChemAxon
Polarizability27.43 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as hexamethonium compounds. These are organic compounds containing a N,N,N,N',N',N'-hexamethylhexane-1,6-diaminium moiety.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Quaternary ammonium salts
Direct Parent
Hexamethonium compounds
Alternative Parents
Tetraalkylammonium salts / Organopnictogen compounds / Organic salts / Hydrocarbon derivatives / Amines / Organic cations
Substituents
Hexamethonium / Tetraalkylammonium salt / Organopnictogen compound / Hydrocarbon derivative / Organic salt / Amine / Organic cation / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
quaternary ammonium salt (CHEBI:5700)

Drug created on May 28, 2014 16:19 / Updated on October 02, 2017 06:11